Latest Annual Report
Sign up for email alerts
Be the first to receive breaking newsSign up today
Lion Biotechnologies is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs). Our TIL technology, which was developed at National Cancer Institute and is currently in use at leading US cancer centers, has demonstrated robust efficacy in metastatic melanoma and is potentially applicable to all solid tumors. As we continue advancing our current clinical programs, we are also developing next-generation TILs and an optimized manufacturing process that will enable the production of highly potent, engineered cells at a significantly reduced cost. With unique and versatile technology, promising clinical programs, strong intellectual property, high-profile collaborations and seasoned leadership, we believe Lion has the potential to create meaningful value for its stakeholders.